Count Me In is aiming to sign up more than 100,000 patients across all major cancer types, as well as rare cancers, over the next several years.
The five startup companies are focused on molecular diagnostics, precision oncology, personalized medicine, and more.
With the three-year grants, the institutions will continue an initiative that is developing tools and technologies for genome biology research.
DiaCarta scientists will partner with the University of Florida Health Cancer Center to analyze blood samples from up to 500 cancer patients undergoing radiotherapy.
A $5 million NIH grant will fund CPIC's ongoing work to develop PGx guidelines and an API for incorporating them into EHRs and clinical decision support systems.
The technology uses a conducting polymer-based electrochemical chip with an array of electrodes and employs an electrical field to release and detect mutations.
Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.
The funding, spread over 89 awards, includes grants for molecular and genomics research efforts across multiple institutions, by early-career and otherwise innovative scientists.
The NHS will expand on existing efforts such as the 100,000 Genomes Project and will offer people with rare diseases the opportunity to sequence their genomes.
The firm will use the funding to develop and validate an expanded version of its somatic cancer hotspot and monitoring assays.
The technology is capable of measuring the concentration and size of extracellular vesicles as small as 40 nanometers and requires no sample labeling.
The increase is part of a larger appropriations package that has cleared the Senate and has now been sent to President Trump for his signature.
HuBMAP is not anticipated to map the entire body, but to provide a framework for more complete mapping and make data available to the research community.
The institutes will lead a consortium of researchers investigating the molecular underpinnings of diabetic retinopathy, a key cause of blindness.
The funding is being provided by three charities under a program designed to facilitate collaboration between research groups from different institutions.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
The company will use the funds to develop and refine proprietary algorithms for identifying more complex variants including translocations and inversions.
The appropriations package would boost the NIH's fiscal 2019 budget to $39.1 billion, and earmarks money for programs such as the All of Us initiative.
The firm will use the funds to advance its high-throughput single-cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.
UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.
Two researchers are calling for education for scientists on defending facts.
Researchers were among those who marched in London this weekend to call for another vote on Brexit.
Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.